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May 20101322 Abstractswith TEVAR was impressive. With longer follow-up, this may translate into
improved survival with fewer long-term complications.
Stent Graft versus Balloon Angioplasty for Failing Dialysis-Access
Grafts
Haskal ZJ, Trerotola S, Dolmatch B, et al. N Engl J Med 2010;362:494-
503.
Conclusion: Revision of a venous anastomotic stenosis of a prosthetic
dialysis access graft with a stent graft provides longer-term patency and
freedom from repeat intervention than revision with standard balloon an-
gioplasty.
Summary: Secondary patency of hemodialysis grafts is at best 50% at 3
years. Many interventions are typically required to maintain dialysis-access
graft patency. The authors sought to test the hypothesis that revision of
venous anastomotic stenosis with stent grafts constructed with the same
material as the dialysis-access graft itself would improve long-term patency
compared with that provided by revision with balloon angioplasty alone.
Theoretically, stent graft revision would prevent elastic recoil associated with
balloon angioplasty alone and prevent intimal hyperplasia in-growth at the
venous anastomosis, resulting in improved patency of the revised grafts.
This was a prospective multicenter trial. There were 190 patients
undergoing hemodialysis with dialysis-access grafts and a venous anastomo-
sis stenosis that were randomly assigned to receive balloon angioplasty alone
or balloon angioplasty plus placement of a stent graft at the site of the venous
anastomotic lesion. Patency of the treatment area and patency of the entire
vascular access graft were the primary end points.
At 6months, patency of the treatment area was greater in the stent graft
group than in the balloon angioplasty group (51% vs 23%, P  .001).
Six-month patency of the dialysis access circuit was improved in the stent
graft group vs the balloon angioplasty group (38% vs. 20%, P  .008).
Freedom from subsequent intervention at 6 months was also greater in the
stent graft group than in the balloon angioplasty group (32% vs 16%, P 
.03). Restenosis was greater in the balloon angioplasty group than in the
stent graft group (78% vs 28%, P .001). Other adverse events at 6 months
were equivalent in the two treatment groups.
Comment: There is still a need for dialysis-access grafts. Results of this
study suggest stent grafts provide better patency in treating venous anasto-
motic strictures of dialysis-access grafts than that provided by balloon
angioplasty alone. Although the results are statistically significant, there are
details to be considered before declaring the results clinically significant.
Grafts in this study were treated before actual thrombosis.Many access grafts
do not come to revision until they have thrombosed, and it is controversial
whether surveillance and treatment of patent, but not thrombosed dialysis
grafts, actually results in overall prolongation of usable access. In addition, 6
months after revision with a stent graft, there is primary patency in only half
the patients. Stent grafts are more expensive than balloon angioplasty alone.It is therefore unclear whether the increased patency at 6 months will
translate into longer-term cost-effectiveness and whether an approach of
graft surveillance with treatment with this technology of narrowed venous
anastomotic areas discovered with surveillance will result in meaningful
overall clinical benefit or cost savings.
White Blood Cell Count Predicts All-cause Mortality in Patients with
Suspected Peripheral Arterial Disease
Arain FA, Khaleghi M, Bailey KR, et al. Am J Med 2009;122:874.e1-
874.e7.
Conclusion: The white blood cell (WBC) count provides incremental
information about risk of death in patients with peripheral arterial disease
(PAD).
Summary: Inflammation is felt to play a central role in the develop-
ment and progression of atherosclerosis. Markers of inflammation associated
with higher rates of adverse cardiovascular outcome include C-reactive
protein (CRP) and WBC count as well as lipoprotein-associated phospho-
lipase A2. The authors postulated that increased plasma levels of CRP and
lipoprotein-associated phospholipase A2, as well as the WBC count, would
be associated with increased mortality in patients with suspected PAD
referred to a vascular laboratory.
The study population was derived from 242 patients (54% men; mean
age, 68 years) referred to a vascular laboratory. Ankle-brachial index (ABI)
and inflammatory markers were measured at the start of the study. Fifty-six
patients (25%) died in follow-up. Death was associated with increased age,
history of cerebrovascular or coronary artery disease, increased creatinine
level, lower ABI, increasedWBC count, and increased CRP level. Patients in
the top tertile of WBC count and CRP level had a relative risk of death of
3.37 (95% confidence interval, 1.56-7.27) and 2.12 (95% confidence inter-
val, 0.97-4.62), respectively. Lipoprotein-associated phospholipase A2 was
not associated with all-cause mortality. Only WBC count incrementally
contributed to prediction of mortality. Inferences were the same when
analysis was limited to patients with ABIs 0.9.
Comment: The data show indicators of systemic inflammation are
associated with higher mortality in patients referred to a vascular laboratory.
This study does not answer the question of whether WBC count is simply a
marker of inflammation or has an independent pathologic role. The top
tertile of WBC count in this study was defined 7.9  103/ml3; thus,
even patients with so-called normal WBC counts and PAD are at in-
creased risk of death. However, only about half of the patients were using
antiplatelet or statin medications, and it is unclear in the patients using
these medications over what proportion of the follow-up these medica-
tions were used. Before we start checking WBC counts in patients with
suspected PAD, this study will need to be repeated with patients who are
receiving aspirin and statin therapy.
